

Multi-omic spatial data integration resolves immunometabolic heterogeneity associated with Nivolumab response in non-small cell lung cancer (NSCLC) patients



Raymond Yan¹, Shannon Quinn¹, Brian Falkenstein¹, James Monkman², Kenneth O'Bryne^{2,3}, A. Burak Tosun, S Chakra Chennubhotla^{1,4}, **Filippo Pullara¹**, Arutha Kulasinghe²


¹PredxBio, Inc., 100 S. Jackson Ave., Pittsburgh, PA USA 15202; ²Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; ³Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia; ⁴ Dept. of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, USA

Background

- Non-Small Cell Lung Cancer (NSCLC) accounts for most lung cancers and has a poor 5-year survival.
- Spatial intratumoral heterogeneity of the tumor microenvironment (TME) is not well-understood for NSCLC contributing to ineffective immunotherapies (ICI).
- Advanced multiplex techniques in both spatial proteomics and spatial transcriptomics are currently used for generating novel hypotheses on immunometabolic pathway crosstalk, developing predictive spatial biomarkers and targeting metabolic determinants of immunotherapy response.

Methods


- Study performed on a retrospective cohort of *second-line nivolumab-treated* NSCLC tissue cores – **N = 28 (responders = 10/non-responders = 18)** [1].
- Cohort was profiled using a **custom 44-plex mIF panel** [1] (incl. functional/metabolic markers) with the Phenocycler Fusion platform (Akoya Biosciences) and ROI-based bulk transcriptomics (Nanosttring GeoMx DSP, 1812 curated genes) and co-registered through alignment of DAPI.
- We applied **SpacelIQ™** [2,3], an unbiased spatial analytics and explainable AI platform, for mIF markers-based cell segmentation & unbiased cell typing on entire tissue cores.
- Cell type-specific gene expression profiles were estimated through RNA deconvolution on 147 differentially expressed genes.
- Outcome-specific microdomains were then derived using pointwise-mutual information (PMI) [4] on the core-based cell types.
- Microdomain-guided gene pathway enrichment and significant proteomic biomarker pathways were annotated based on Ingenuity Pathway Analysis and STRING database, respectively.




Results

- Microdomain discovery from core-based cell types resulted in a distinct set of enriched pathways from multi-omic integration of mIF and DSP bulk RNA data.
- Predictive performance between the two approaches using spatial transcriptomics and spatial proteomics yielded comparable performances.
- ROI-based microdomains implicated lipid metabolism (p=0.02), fatty acid oxidation (p=0.04), Notch Signaling (p=0.01), and NK-mediated activity (p=0.06) in nivolumab-treated response.
- Core-based microdomains were enriched for cell differentiation (p<0.01), mitochondrial metabolism / TCA (p=0.01), and lymphocyte trafficking (p=0.08).

Unbiased Cell Typing Extracts Numerically Stable, Spatially Distinct and Biologically Interpretable Recursive Cell Types




Unbiased Cell Typing Reveals Differential Metabolic Activity in Tumor (Stroma) Cell Types in Non-Responders (Responders)



Conclusions


- The SpacelQ platform enables **integration of mIF and RNA expression** data from Nivolumab-treated NSCLC tissue samples to discover microdomains associated with treatment response.
- Microdomains associated with treatment response** suggest the role of canonical metabolic programs and immune cell differentiation/migration in improved outcomes.
- Further investigation in the immuno-metabolic states within the TME will lead to more **effective ICI treatment strategies for NSCLC**.

Microdomains Emerge as Spatial Networks of Immuno-Metabolic Cell Types




Microdomain	Cell Types	Proteomic Mean AUC (SD)
1	'11000', '12122', '21220', '22112'	0.75 (0.12)
2	'12111', '12111', '12222'	0.75 (0.15)
3	'12120', '12111', '12222'	0.84 (0.12)
4	'12211', '12212', '12222', '11111', '21212'	0.73 (0.14)
5	'12211', '12212', '12222', '21112', '21212'	0.70 (0.13)
6	'12211', '12212', '11111', '21212', '22111'	0.67 (0.13)
7	'12211', '12212', '11112', '21212', '22111'	0.69 (0.12)
8	'12211', '12222', '11111', '21212', '22111'	0.75 (0.12)
9	'12211', '12222', '11111', '21212', '22220'	0.84 (0.12)
10	'12211', '12222', '21112', '21212', '22111'	0.72 (0.13)
11	'12211', '12222', '21212', '21212', '22112'	0.72 (0.13)
12	'12211', '12222', '21212', '22120', '22111'	0.72 (0.12)
13	'12211', '21212', '22111', '22120'	0.68 (0.13)

Microdomains are Spatially Distinct Catabolic and Anabolic Programs that Predict ICI Response



Microdomains are highly predictive of overall survival and response. Some microdomains are spatially anchored around tumor cells with upregulated TCA cycle and oxidative phosphorylation (OXPHOS) with additional NK cells and dendritic cells along with upregulated PPP. Some microdomains capture spatially distinct metabolic programs relating to catabolic (energy utilization) and anabolic (cellular biogenesis) pathways.




References

- ^[1]Monkman et al. Immunology, 2023; ^[2]Uttam, S, et al Nat. Comm., 2020;
- ^[3]Furman SA, Cell. Rep. Met., 2021; ^[4]Spagnolo D et al, JPI, 2016

Contact:


- Chakra Chennubhotla, PhD
chakra@predxbio.com (or)
chakracs@pitt.edu
- Arutha Kulasinghe, PhD
arutha.kulasinghe@uq.edu.au



Read SpacelQ White Paper



Follow us on LinkedIn



PUBLICATIONS